Personalized immune cells target advanced prostate cancer in new trial
NCT ID NCT07285694
Summary
This trial is testing whether modified immune cells can help control advanced prostate cancer that has stopped responding to standard hormone treatments. Doctors take a patient's own immune cells, modify them to recognize prostate cancer proteins, and infuse them back into the body. The study aims to find the safest dose and see if this approach can help shrink tumors in men whose cancer has spread and progressed despite previous treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Perlmutter Cancer Center - NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
-
University of Iowa and Holden Comprehensive Cancer Center
RECRUITINGIowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.